Search research articles
Contact Us
Filters
Showing results (471-480 of 517) with videos related to
Page
of 52
Sort By:
Surgical Oncology
|
June 21, 2020
A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience
Cinthya Y Lowder, Teena Dhir, Austin B Goetz, et al.
Genes, Chromosomes & Cancer
|
January 27, 2017
Alterations of type II classical cadherin, cadherin-10 (CDH10), is associated with pancreatic ductal adenocarcinomas
Natini Jinawath, Meng-Shin Shiao, Alexis Norris, et al.
Molecular Cancer Research : MCR
|
April 8, 2016
HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells
Carmella Romeo, Matthew C Weber, Mahsa Zarei, et al.
British Journal of Cancer
|
July 12, 2019
Multi-omic molecular comparison of primary versus metastatic pancreatic tumours
Gagandeep Brar, Edik M Blais, R Joseph Bender, et al.
Biorxiv : the Preprint Server for Biology
|
April 28, 2025
Post-transcriptional regulator HuR promotes immune evasion in pancreatic ductal adenocarcinoma
Yifei Guo, Jennifer M Finan, Alexandra Q Bartlett, et al.
The Lancet. Oncology
|
March 6, 2020
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
Michael J Pishvaian, Edik M Blais, Jonathan R Brody, et al.
JCO Precision Oncology
|
February 1, 2022
Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program
Michael J Pishvaian, Edik M Blais, Jonathan R Brody, et al.
Plos One
|
December 15, 2010
pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs
Timothy K Williams, Christina L Costantino, Nikolai A Bildzukewicz, et al.
Cancer Research
|
February 19, 2014
HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells
Shruti Lal, Richard A Burkhart, Neil Beeharry, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association
|
September 22, 2009
Single nucleotide polymorphism in RECQL and survival in resectable pancreatic adenocarcinoma
Ronald T Cotton, Donghui Li, Steven E Scherer, et al.
Page
of 52
Search research articles
Search
Showing results (471-480 of 517) with videos related to
Sort By:
Page
of 52
Surgical Oncology
|
June 21, 2020
A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience
Cinthya Y Lowder, Teena Dhir, Austin B Goetz, et al.
Genes, Chromosomes & Cancer
|
January 27, 2017
Alterations of type II classical cadherin, cadherin-10 (CDH10), is associated with pancreatic ductal adenocarcinomas
Natini Jinawath, Meng-Shin Shiao, Alexis Norris, et al.
Molecular Cancer Research : MCR
|
April 8, 2016
HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells
Carmella Romeo, Matthew C Weber, Mahsa Zarei, et al.
British Journal of Cancer
|
July 12, 2019
Multi-omic molecular comparison of primary versus metastatic pancreatic tumours
Gagandeep Brar, Edik M Blais, R Joseph Bender, et al.
Biorxiv : the Preprint Server for Biology
|
April 28, 2025
Post-transcriptional regulator HuR promotes immune evasion in pancreatic ductal adenocarcinoma
Yifei Guo, Jennifer M Finan, Alexandra Q Bartlett, et al.
The Lancet. Oncology
|
March 6, 2020
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
Michael J Pishvaian, Edik M Blais, Jonathan R Brody, et al.
JCO Precision Oncology
|
February 1, 2022
Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program
Michael J Pishvaian, Edik M Blais, Jonathan R Brody, et al.
Plos One
|
December 15, 2010
pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs
Timothy K Williams, Christina L Costantino, Nikolai A Bildzukewicz, et al.
Cancer Research
|
February 19, 2014
HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells
Shruti Lal, Richard A Burkhart, Neil Beeharry, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association
|
September 22, 2009
Single nucleotide polymorphism in RECQL and survival in resectable pancreatic adenocarcinoma
Ronald T Cotton, Donghui Li, Steven E Scherer, et al.
Page
of 52